Sugi Predict

Sugi Predict / Compounds / SCHEMBL13912

SCHEMBL13912

SCHEMBL13912

CC(=O)Nc1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.75
▸ MEN1 O00255 3/20 0.75
▸ MAPT P10636 2/20 0.75
▸ GAA P10253 2/20 0.75
▸ KDM4E B2RXH2 1/20 0.75
▸ ALDH1A1 P00352 1/20 0.75
▸ CYP1A2 P05177 1/20 0.73
▸ CYP3A4 P08684 1/20 0.73
▸ CYP2C19 P33261 1/20 0.73
▸ GFER P55789 1/20 0.73
▸ RAB9A P51151 9/20 0.66
▸ NPC1 O15118 8/20 0.66
▸ JAK2 O60674 1/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ TSHR P16473 1/20 0.59
▸ CHRNA10 Q9GZZ6 1/20 0.58
▸ CHRNA9 Q9UGM1 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28106923 0.86 RAB9A (0.70) KMT2AMEN1MAPTGAAKDM4E
SCHEMBL9382745 0.86 MAPT (0.75) KMT2AMEN1MAPTGAAKDM4E
SCHEMBL975489 0.86 MAPT (1.00) KMT2AMEN1MAPTGAAKDM4E
SCHEMBL30620451 0.85 MAPT (1.00) KMT2AMEN1MAPTGAAKDM4E
SCHEMBL1430921 0.85 RAB9A (0.64) KMT2AMEN1GAARAB9ANPC1
SCHEMBL6689700 0.84 GFER (1.00) KMT2AMEN1MAPTGAAKDM4E
SCHEMBL14365697 0.83 RAB9A (0.62) KMT2AMEN1GAARAB9ANPC1
SCHEMBL14829004 0.83 MAPT (0.71) KMT2AMEN1MAPTGAAKDM4E
SCHEMBL14829005 0.83 MAPT (0.71) KMT2AMEN1MAPTGAAKDM4E
SCHEMBL10683082 0.83 KMT2A (0.71) KMT2AMEN1MAPTGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO claimed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
US-20250339425-A1 Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands UNIV NORTHEASTERN (US) 2025-11-06 — — US disclosed
CN-110857300-B Condensed ring triazole compounds, preparation method and application 上海凌达生物医药有限公司 2021-11-05 — — CN disclosed
CN-109721600-B Nitrogen-containing fused ring compounds and preparation method and application thereof 上海凌达生物医药有限公司 2021-04-27 — — CN disclosed
CN-110857300-A Condensed ring triazole compounds, preparation method and application 如东凌达生物医药科技有限公司 2020-03-03 — — CN disclosed
WO-2020038458-A1 CLASS OF FUSED RING TRIAZOLE COMPOUND, PREPARATION METHOD, AND USE 如东凌达生物医药科技有限公司 2020-02-27 — — WO disclosed
WO-2020038458-A1 CLASS OF FUSED RING TRIAZOLE COMPOUND, PREPARATION METHOD, AND USE 如东凌达生物医药科技有限公司 2020-02-27 — — WO disclosed
US-9346799-B2 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors BASILEA PHARMACEUTICALS AG (CH) 2016-05-24 — — US disclosed
US-20160122320-A1 USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS BASILEA PHARMACEUTICA AG (CH) 2016-05-05 — — US disclosed
EP-2760823-A1 NOVEL COMPOUNDS AS HIF-1ALPHA INHIBITORS AND MANUFACTURING PROCESS THEREOF Dongguk University Industry-Academic Cooperation Foundation (KR) 2014-08-06 — — EP disclosed
EP-2484680-B1 Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors BASILEA PHARMACEUTICA AG (CH) 2013-06-26 — — EP disclosed
WO-2013048164-A1 NOVEL COMPOUNDS AS HIF-1αINHIBITORS AND MANUFACTURING PROCESS THEREOF DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2013-04-04 — — WO disclosed
EP-2484680-A1 Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors Basilea Pharmaceutica AG (CH) 2012-08-08 — — EP disclosed
EP-1965798-B1 USEFUL MONOBACTAM ANTIBIOTICS BASILEA PHARMACEUTICA AG (CH) 2011-10-19 — — EP disclosed
WO-2011047323-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 — — WO disclosed
EP-2308874-A1 Useful beta-lactamase inhibitors Basilea Pharmaceutica AG (CH) 2011-04-13 — — EP disclosed
US-20100056478-A1 Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors BASILEA PHARMACEUTICA AG (CH) 2010-03-04 — — US disclosed
US-20100056478-A1 Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors BASILEA PHARMACEUTICA AG (CH) 2010-03-04 — — US disclosed
WO-2007065288-A2 USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS BASILEA PHARMACEUTICA AG (CH) 2007-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339425-A1 Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands CHRNA9, CHRNA7, CHRNA1 KMT2A 4063/4885MEN1 4006/4885MAPT 2177/4885
US-20160122320-A1 USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS MGAM, MGAM2, B2M KMT2A 1169/4885MEN1 2778/4885MAPT 3122/4885
US-20100056478-A1 Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors MGAM, MGAM2, B2M KMT2A 1199/4885MEN1 2610/4885MAPT 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.